# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
MOLN: 11% | Molecular Partners shares are trading higher after the company announced the debut of their lead Raido-DARPin thera...
Mechanism of action supported by observed MP0317 localization and immune cell activation in the tumor microenvironment Favor...
Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while s...
Molecular Partners (NASDAQ:MOLN) reported quarterly losses of $(2.13) per share which missed the analyst consensus estimate of ...